FibroBiologics annual return on equity
2024
2025
FibroBiologics Return on Equity (ROE) Growth & History (FBLG)
FibroBiologics's return on equity was −419.44% for fiscal 2025.
View full FibroBiologics company overviewFibroBiologics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −419.44% | +140.29 pp |
| 2024 | 2024-12-31 | −559.73% | — |
FibroBiologics quarterly return on equity
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −113.79% | +176.43 pp |
| Q1 2026 | 2026-03-31 | −114.21% | +81.11 pp |
| Q4 2025 | 2025-12-31 | −103.30% | +9.97 pp |
| Q3 2025 | 2025-09-30 | −1,173.20% | −887.48 pp |
| Q2 2025 | 2025-06-30 | −290.22% | — |
| Q1 2025 | 2025-03-31 | −195.32% | — |
| Q4 2024 | 2024-12-31 | −113.27% | — |
| Q3 2024 | 2024-09-30 | −285.71% | — |
FibroBiologics return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, FibroBiologics's return on equity increased from −559.73% to −419.44%, a change of +140.29 percentage points. The latest reported quarter, Q2 2026, shows −113.79%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review FibroBiologics source filings ↗